Check out your Company Bowl for anonymous work chats.
Building trust in communities that have been historically underrepresented in clinical studies is an important step to expanding diversity in clinical trials. Andrew Trister, MD PhD, our Chief Medical and Science Officer discussed strategies to make progress while at the recent Milken Institute Global Conference: “Clinical trials are more successful when participants feel like they’re centered in the process. One way to reflect this is in the language associated with clinical trial participation.” “Even the language that we use when we talk about clinical studies represents a change in the hierarchy and shifts how the trust relationship works — a person becomes a subject in a study as opposed to being a patient.”
Living with a disability can encompass a wide range of experiences. Building accessible and inclusive solutions requires us to consider these needs early in the product development lifecycle so that we build with and for everyone. At Verily, some of our best practices for diversity by design include: ▶ Accessibility and inclusion principles integrated throughout our product design system ▶ User research and focus groups with individuals from historically marginalized communities ▶ Internal awareness and education through our disability-focused employee resource group
Meet Stephen Gillett, Verily Chairman and CEO, at Fortune Brainstorm Health next Tuesday, May 21. He’ll join Bob Segert of athenahealth, Andrea Downing of The Light Collective, and moderator Andrew Nusca to discuss the growing threat of cybersecurity breaches in the healthcare industry and how to build a resilient health system and ensure patient trust.
Exciting news for the ALS research community! Target ALS has added comprehensive datasets from its Natural History Study to their data portal. The portal uses Verily Workbench, a collaborative research environment for governing and analyzing global multimodal data to fuel discovery of treatments and biomarkers for ALS.
Diabetes management is overwhelming and complex. We get it. Through data-driven in-app activities and dedicated care team support, Onduo, our virtual care solution, can support better diabetes self-management and lasting, healthier habits. It helps to make doing the right thing, the easy thing.
We are thrilled to see Dan Doctoroff,Target ALS Founder and Chairman, on the list of TIME100 Most Influential People in Health of 2024. Over the past decade, he has been dedicated to progressing ALS research and in 2021, after being diagnosed with ALS himself, Doctoroff made it his full-time focus. Target ALS uses Verily Workbench to securely access and analyze multimodal ALS data in order to better understand the disease and advance treatment. We are proud to partner with them on this important initiative.
When designing clinical trials, what does it mean to meet patients where they are? Andrew Trister, MD PhD, our Chief Medical and Science Officer, answered this question at the Milken Institute Global Conference, referencing the use of wearables and observational studies. "Collecting data outside the traditional confines of the clinical study or health system can be very helpful in determining how these drugs, devices and tools really do impact health." “This type of real-world data can be a huge augmentation to the way that we understand health and disease and the way that people are living.” Dr. Trister went on to talk about another layer of data, leveraging experience – “take what you learn from each patient and apply it to the next.”
Integrating data from many sources is critical to improve health outcomes research. At ISPORAnnual 2024, the plenary session featuring our Head of Strategic Affairs Joe Franklin focused on how we can address the complexities of data linkage and drive towards a common understanding of fit-for-purpose approaches for evidence generation. Our team also shared results from the Project Baseline Health Study, highlighting findings on remote participant engagement and the validity of remote screening for symptoms of depression.
In response to the recent detection of H5N1, in partnership with WastewaterSCAN collaborators, Verily Principal Scientist Bradley White and team developed an assay to detect H5 in wastewater samples and further researched the detection of H5 in wastewater. Verily’s initial use of the assay focused on testing wastewater samples from select areas in Texas, the apparent epicenter of new cases, revealing the presence of H5 IAV nucleic acid in wastewater samples collected shortly before and during the reported dairy cattle cases. The findings suggest that wastewater testing can serve as a public health monitoring tool by detecting new and emerging animal pathogens with zoonotic potential, like H5. Our work is ongoing. Read more in the paper co-authored by researchers from Rollins School of Public Health at Emory University, Verily and Stanford University School of Engineering
Next week at the Milken Institute Global Conference, our Chief Medical and Science Officer Andrew Trister will discuss ways to revolutionize research and democratize clinical trials through the use of technology and a data-driven approach centered around the patient. The session is on Wednesday, May 8 at 8:30am PT.
